Distribution of Anti-EBV Antibodies in HIV-1 Positive Individuals - Johnson, Newell;Wanzala, Peter
36,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
18 °P sammeln
  • Broschiertes Buch

Human Herpes Virus Type 4 or Epstein Barr Virus is known to exert its oncogenic potential in altered immune states, HIV/AIDS being one of them. The HHV4 life cycle involves the continuous production of various latent and lytic proteins. In HIV infection antibodies to non HIV micro-organisms is erratic because the entire immune system is trying to combat the rapidly replicating HIV. HIV associated tumors appear in HIV clinical stage 3. Literature has not been able to demonstrate, in an HIV positive population, the association of HIV clinical staging with EBV antibodies and EBV infection…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Human Herpes Virus Type 4 or Epstein Barr Virus is known to exert its oncogenic potential in altered immune states, HIV/AIDS being one of them. The HHV4 life cycle involves the continuous production of various latent and lytic proteins. In HIV infection antibodies to non HIV micro-organisms is erratic because the entire immune system is trying to combat the rapidly replicating HIV. HIV associated tumors appear in HIV clinical stage 3. Literature has not been able to demonstrate, in an HIV positive population, the association of HIV clinical staging with EBV antibodies and EBV infection clinical stages . Virologists and clinicians who are interested in the interaction of HIV and other oncogenic viruses will find this a valuable addition to their knowledge.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Melvin D'lima BDS. Studied MSc (Public Health) at Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya. He has a keen interest in the epidemiology of oncogenic viruses especially in HIV 1 positive patients. He is currently CEO at Wealth in Healthcare which empowers health workers to start and grow their private enterprises.